Malignancy risk in systemic Lupus Erythematosus patients treated with cyclophosphamide

dc.authoridKaradag, Omer/0000-0002-3443-3117
dc.authoridOzen, Gulsen/0000-0002-5423-393X
dc.authoridAksu, Kenan/0000-0001-8889-2688
dc.authoriderken, eren/0000-0001-6902-624X
dc.authoridCoşkun, Belkıs Nihan/0000-0003-0298-4157
dc.authoridKaradag, Omer/0000-0002-3443-3117
dc.authoridYıldız, Fatih/0000-0003-3628-8870
dc.authorwosidKaradag, Omer/AAR-4219-2020
dc.authorwosidOzen, Gulsen/J-4547-2016
dc.authorwosidAksu, Kenan/HLH-8218-2023
dc.authorwosiderken, eren/L-3219-2019
dc.authorwosidCoşkun, Belkıs Nihan/AAG-7155-2021
dc.authorwosidKaradag, Omer/AAD-5448-2019
dc.authorwosidYıldız, Fatih/P-2555-2018
dc.contributor.authorYilmaz, N.
dc.contributor.authorEmmungil, H.
dc.contributor.authorGucenmez, S.
dc.contributor.authorOzen, G.
dc.contributor.authorYildiz, F.
dc.contributor.authorBalkarli, A.
dc.contributor.authorKimyon, G.
dc.date.accessioned2024-06-12T11:24:01Z
dc.date.available2024-06-12T11:24:01Z
dc.date.issued2015
dc.departmentTrakya Üniversitesien_US
dc.description11th International Congress on Systemic Lupus Erythematosus -- SEP 02-06, 2015 -- Vienna, AUSTRIAen_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.endpageS67en_US
dc.identifier.issn0392-856X
dc.identifier.issn1593-098X
dc.identifier.issue3en_US
dc.identifier.startpageS67en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/26776
dc.identifier.volume33en_US
dc.identifier.wosWOS:000360421900240en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherClinical & Exper Rheumatologyen_US
dc.relation.ispartofClinical And Experimental Rheumatologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleMalignancy risk in systemic Lupus Erythematosus patients treated with cyclophosphamideen_US
dc.typeConference Objecten_US

Dosyalar